Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Guidant shareholders approve J&J merger
The agreement, which was announced on December 15, 2004, remains subject to European and US regulatory review, as well as other customary closing conditions. The terms of the
The agreement, which was announced on December 15, 2004, remains subject to European and US regulatory review, as well as other customary closing conditions. The terms of the
The final approval of the generic 500mg, 750mg and 1000mg Niaspan tablets follows the expiration of Kos’ 30-month stay under the Hatch-Waxman patent challenge provisions and the resolution
These collaborations will utilize ParAllele’s application-specific single nucleotide polymorphism (SNP) genotyping panel that is being commercialized as part of an existing development partnership with Affymetrix. The new panel
The study was designed to evaluate the pharmacokinetic (PK) profiles of various doses of NovaDel’s lingual spray compared to a 0.5mg alprazolam tablet (Xanax). NovaDel achieved its goal
The primary task of the study is to evaluate the biodistribution of indomethacin, the active ingredient in Indaflex, after either oral or topical administration of appropriate formulations in
ISIS 369645 is a second-generation antisense inhibitor of the alpha subunit of the interleukin 4 receptor, IL4R-alpha. Inhibiting the production of the IL4R-alpha inhibits the activity of two
The Aeras Global TB Vaccine Foundation is an international non-governmental organization currently funded by the Bill & Melinda Gates Foundation and the US Centers for Disease Control and
MPC-6827 is being developed by Myriad from a family of anticancer analogs discovered by Maxim through its proprietary high-throughput screening system, which identifies compounds and molecular targets that
PW2101 is intended for the treatment of hypertension and angina and is currently under review by the FDA. The Prescription Drug User Fee Act (PDUFA) target action date
The ophthalmic product will be developed for the treatment of steroid-responsive inflammatory ocular conditions where risk of bacterial infection exists. The product is a fixed combination of tobramycin